Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunological Responses

Weide et al., American Association for Cancer Research (2014) - PMID: n.a

Product(s) used in this publication: PepMix™ Peptide Pools

Sorry, currently there is no abstract available.

Stay in touch and be the first to receive the latest news!